This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

US appeals court turns down Niaspan end-payors' attempt at class certification in antitrust case

( May 4, 2023, 22:33 GMT | Official Statement) -- MLex Summary: AbbVie and Teva Pharmaceuticals got a US appeals court to rule in their favor against class certification in a case accusing them of conspiring to delay generic Niaspan. The US Court of Appeals for the Third Circuit affirmed an order denying certification, saying that the lower court did not err on the factual findings or the legal standard, and it is not at liberty to reconsider its ascertainability requirement in its entirety. See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections